Prostate cancer

HCA Healthcare UK is committed to the diagnosis and treatment of men's health issues across the board. Our consultants are experts in men's health and uro-oncology and our clinical staff work together as a team to provide innovative and evidence-based care.

HCA UK offers a wide range of services and treatments which could make a positive difference to someone's life.

Regardless of whether you, or a family member or friend, believe you have a potential men's health issue - get in contact with us today to receive expert advice and information.

Types of prostate cancer

• Acinar adenocarcinoma

  : Adenocarcinoma is a type of prostate cancer that develops in the cells that line the prostate gland.

• Ductal adenocarcinoma

  : Ductal adenocarcinoma cancer starts in the cells that line the ducts of the prostate gland and tend to grow quickly.

• Transitional cell (or urothelial) cancer

  : This type of prostate cancer usually starts in the bladder and spreads into the prostate.

• Squamous cell carcinoma

  : Squamous cell carcinoma develops from flat cells that cover the prostate and can spread quickly.

• Small cell prostate cancer

  : This is a type of cancer affecting the nerves and small, round cells.

• Other rare prostate cancers

  : Carcinoid is a tumour that develops when nerve cells start to grow out of control. Sarcoma is a cancer that develops from the soft tissue.

How we help you

HCA Healthcare UK is committed to giving you the most advanced, personalised cancer treatment and care. Our cancer care network is spread across the UK. This includes our own private hospitals, private units within leading NHS hospitals and dedicated chemotherapy and radiotherapy centres. We offer patients rapid access to our prostate screening service, where any potential problems can be detected, diagnosed and treated at an early stage by working with a team of healthcare professionals, each with their own area of expertise.

When it comes to treatment, we partner with world-renowned cancer research institute, Sarah Cannon Research Institute. This gives you access to more treatment options including new and emerging drugs. We’re the only private provider to cover the entire patient pathway seamlessly, from diagnosis and treatment, through to clinical trials, survivorship and aftercare.